7 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Multisystem Cell Therapy for Improvement of Urinary Continence (MUSIC)
Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,
... with NMES and to further improve its feasibility and clinical efficacy. The ultimate goal is to significantly improve the patients` quality of life and to exploit a future commercial opportunity by expanding the know-how to various smaller RM centers and companies within Europe, thus, making personalized medicine using autologous cells a more feasible SUI treatment option."
Voir le projet
5
Participants partenaires
TERMINÉ
Stem-cell based therapy for kidney repair (STELLAR)
Date du début: 1 nov. 2012, Date de fin: 31 oct. 2017,
Chronic kidney disease (CKD) affects 8% of the European population and ultimately results in renal failure due to progressive fibrosis. CDK carries a high mortality risk and the number of affected people rises, increasing the demand on renal replacement therapies while the number of available donor organs stays stable.The STELLAR consortium proposes to develop an alternative to renal replacement ...
Voir le projet
15
Participants partenaires
TERMINÉ
Rapid Prototyping of Custom-Made Bone-Forming Tissue Engineering Constructs (RAPIDOS)
Date du début: 1 juil. 2013, Date de fin: 30 juin 2017,
"In cranio-maxillofacial surgery, large blow-out orbital floor fractures have still mitigated outcomes and improved scaffold solutions are needed. The reconstruction of large bone defects in proximal femur or proximal tibia in orthopaedic surgery is also an enormous challenge due to the requirements for both complex shape and partial load bearing ability. This is the goal of this European and Chin ...
Voir le projet
4
Participants partenaires
TERMINÉ
Growing bone fast and cost-effective (CHARME)
Date du début: 1 juil. 2015, Date de fin: 30 juin 2017,
XPAND Biotechnology BV has developed a new generation of orthopaedic materials: the EpitaxOs bone regeneration material. EpitaxOs (TRL 6) is unique:a) it seduces the body to form boneb) is as effective as the golden standard autograft without its disadvantages (extra operative procedure, pain, limited quantity available)c) it is superior to other synthetic bone graft materials, allograft, growth f ...
Voir le projet
1
Participant partenaire
TERMINÉ
bioREACtor for stem cell tHerapy (REACH)
Date du début: 1 juil. 2013, Date de fin: 30 juin 2016,
The REACH-project is a direct result of the FP7 StemExpand project, which aimed at the expansion and engraftment of hematopoietic and mesenchymal stem cells (MSC) for clinical use. The results of these research activities show that a novel, closed and controlled bioreactor can be developed to grow clinically relevant numbers (>400 million) of MSCs. XPand Biotechnology BV(NL) [bioreactor developmen ...
Voir le projet
4
Participants partenaires
TERMINÉ
Regenerating Bone defects using New biomedical Engineering approaches (REBORNE)
Date du début: 1 janv. 2010, Date de fin: 30 juin 2015,
...boratories, SMEs manufacturing biomaterials, GMP-cell producing facilities and surgeons in hospitals as well as the consideration of ethical and regulatory issues. It is expected that REBORNE will expand the competitiveness of Europe through the patenting of new CE-marked bioproducts in the field of regenerative medicine.
Voir le projet
24
Participants partenaires
TERMINÉ
Stem Cell Expansion - Expansion and engraftment of haematopoietic and mesenchymal stem cells (STEMEXPAND)
Date du début: 1 nov. 2008, Date de fin: 31 oct. 2011,
... stem cells will be defined and subsets of more primitive and more mature mesenchymal stem cells will be identified. Mesenchymal stem cells will also be used to improve engraftment efficiency of the expanded hematopoietic cells and to reduce the frequency of graft versus host disease. The findings are expected to have a great impact on the treatment of serious blood disorders by blood and marrow t ...
Voir le projet